Evidence map›Paper›PMID 31672862›Full record

ArticleScience immunology2019

Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles.

Velislava N Petrova, Bevan Sawatsky, Alvin X Han, Brigitta M Laksono, Lisa Walz, Edyth Parker, Kathrin Pieper, Carl A Anderson, Rory D de Vries, Antonio Lanzavecchia and 4 more

2 registry-linked trialsOpen access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Science immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06923631 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Unravelling the Measles Paradox in Children: a Disease Associated With Both Immune Suppression and Immune Activation

TypeobservationalSponsorErasmus Medical CenterRan2026 to 2029Enrolled100ConditionsMEASLES DISEASE
NCT07267585 recruitingnot on this mapstarted 2025, after this paper: background citation

Unravelling the Measles Paradox: a Disease Associated With Both Immune Suppression and Immune Activation

TypeobservationalSponsorErasmus Medical CenterRan2025 to 2028Enrolled300ConditionsMEASLES DISEASE
3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 131 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Review
  8. Article
  9. Review
  10. Article
  11. Measles virus reprograms CD4Frontiers in cell and developmental biology · 2026
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Childhood B cell leukemia: Intercepting the paths to progression.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024
    Review
  20. What's going on with measles?Journal of virology · 2024
    Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 5 countries.

Velislava N PetrovaDepartment of Human Genetics, Wellcome Sanger Institute, Cambridge, UK. vp5@sanger.ac.uk c.a.russell@amc.uva.nl.ORCID 0000-0001-5997-0173
Bevan SawatskyVeterinary Medicine Division, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines and DZIF TTU Emerging Infections, Langen, Germany.ORCID 0000-0001-6908-1556
Alvin X HanBioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Brigitta M LaksonoDepartment of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, Netherlands.
Lisa WalzVeterinary Medicine Division, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines and DZIF TTU Emerging Infections, Langen, Germany.
Edyth ParkerLaboratory of Applied Evolutionary Biology, Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.ORCID 0000-0001-8312-1446
Kathrin PieperInstitute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.ORCID 0000-0003-4809-3157
Carl A AndersonDepartment of Human Genetics, Wellcome Sanger Institute, Cambridge, UK.ORCID 0000-0003-1719-7009
Rory D de VriesDepartment of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, Netherlands.
Antonio LanzavecchiaInstitute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.ORCID 0000-0002-3041-7240
Paul KellamDepartment of Medicine, Division of Infectious Diseases, Imperial College Faculty of Medicine, Wright Fleming Institute, St Mary's Campus, London, UK.ORCID 0000-0003-3166-4734
Veronika von MesslingVeterinary Medicine Division, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines and DZIF TTU Emerging Infections, Langen, Germany.ORCID 0000-0002-3972-8723
Rik L de SwartDepartment of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, Netherlands.ORCID 0000-0003-3599-8969
Colin A RussellLaboratory of Applied Evolutionary Biology, Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. vp5@sanger.ac.uk c.a.russell@amc.uva.nl.ORCID 0000-0002-2113-162X
Erasmus MC · NLPaul Ehrlich Institut · DEAmsterdam UMC Location University of Amsterdam · NLUniversità della Svizzera italiana · CHWellcome Sanger Institute · GBAgency for Science, Technology and Research · SGBabraham Bioscience Technologies (United Kingdom) · GB

Funding

Wellcome Trust 206194
6 · The paper itself

Abstract

Measles is a disease caused by the highly infectious measles virus (MeV) that results in both viremia and lymphopenia. Lymphocyte counts recover shortly after the disappearance of measles-associated rash, but immunosuppression can persist for months to years after infection, resulting in increased incidence of secondary infections. Animal models and in vitro studies have proposed various immunological factors underlying this prolonged immune impairment, but the precise mechanisms operating in humans are unknown. Using B cell receptor (BCR) sequencing of human peripheral blood lymphocytes before and after MeV infection, we identified two immunological consequences from measles underlying immunosuppression: (i) incomplete reconstitution of the naïve B cell pool leading to immunological immaturity and (ii) compromised immune memory to previously encountered pathogens due to depletion of previously expanded B memory clones. Using a surrogate model of measles in ferrets, we investigated the clinical consequences of morbillivirus infection and demonstrated a depletion of vaccine-acquired immunity to influenza virus, leading to a compromised immune recall response and increased disease severity after secondary influenza virus challenge. Our results show that MeV infection causes changes in naïve and memory B lymphocyte diversity that persist after the resolution of clinical disease and thus contribute to compromised immunity to previous infections or vaccinations. This work highlights the importance of MeV vaccination not only for the control of measles but also for the maintenance of herd immunity to other pathogens, which can be compromised after MeV infection.

Indexed as

AdolescentAnimalsB-LymphocytesChildChild, PreschoolCohort StudiesFerretsHumansImmunosuppression TherapyMaleMeaslesMeasles virusReceptors, Antigen, B-CellReceptors, Antigen, B-Cell

Identifiers

PMID31672862
OpenAlexW2982688247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.